NCI 8628: A randomized phase II study of ziv-aflibercept (Z) and high-dose interleukin-2 (HD IL-2) or HD IL-2 alone for inoperable stage III or IV melanoma—Efficacy and biomarker study. Background: ...

More than 90% of patients with locally advanced basal cell carcinoma (BCC) of the head and neck achieved locoregional control (LRC) with vismodegib (Erivedge) and radiation therapy (RT), a small ...

Please provide your email address to receive an email when new articles are posted on . Vismodegib, an orally administered hedgehog-pathway inhibitor, reduced the new formation and the size of ...

A case report of two patients suggests potential synergy between concurrent vismodegib (Erivedge, Genentech) and radiotherapy for recurrent advanced basal cell carcinoma (BCC). Combining vismodegib ...

Final safety and efficacy results for vismodegib were reported at the Society for Melanoma Research, 2014 International Congress, for the 30-month mark of the ERIVANCE trial. The Congress is meeting ...

The appraisal committee considered evidence submitted by Roche Products and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence.

Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer An observational retrospective study was conducted in nine French ...

Spurred on by these reports, Mohan and colleagues studied the incidence of subsequent non-BCC malignancies in a cohort of 180 patients (68.9% male) with high-risk BCCs (mean age at time of diagnosis, ...

Review the side-effects of Vismodegib as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

The drug vismodegib (trade name: Erivedge) is approved for the treatment of patients with two forms of basal cell carcinoma (BCC): symptomatic metastatic BCC and locally advanced BCC inappropriate for ...